Company Filing History:
Years Active: 2022
Title: Oliver Schlüter: Innovator in Pharmaceutical Compositions
Introduction
Oliver Schlüter is a notable inventor based in Mannheim, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of contact lens-related conditions. His innovative approach has led to the development of a unique pharmaceutical composition that addresses the needs of contact lens wearers.
Latest Patents
Oliver Schlüter holds a patent for "Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lens-related conditions." This patent describes a pharmaceutical composition that includes a semifluorinated alkane of a specific formula. The composition is designed for use in treating or preventing diseases related to the ocular surface of the eye in individuals who wear contact lenses. The application of this composition can occur before, during, or after the use of hydrogel or silicone hydrogel contact lenses.
Career Highlights
Schlüter is associated with Novaliq GmbH, a company that focuses on innovative solutions in the field of ophthalmology. His work at Novaliq has been instrumental in advancing the treatment options available for contact lens wearers. With a patent portfolio that includes 1 patent, he has established himself as a key player in pharmaceutical innovation.
Collaborations
Throughout his career, Oliver Schlüter has collaborated with esteemed colleagues such as Bernhard Günther and Markus Beier. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the development of new pharmaceutical solutions.
Conclusion
In summary, Oliver Schlüter is a pioneering inventor whose work in pharmaceutical compositions has the potential to significantly improve the quality of life for contact lens wearers. His contributions to the field exemplify the importance of innovation in addressing medical challenges.